Manila Times Business
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
G7 protest turns from carnival to violent stand-off
2h ago
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
2h ago
Kaorium Wins Best Digital Innovation at The Fragrance Foundation UK Awards 2026
2h ago
Bambu Lab Store Hits Record-Low Prices -- Including First-Ever Discounts on P2S, H2S and H2C
2h ago